Compare Honeywell International Inc (HON) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs BIO-TECHNE Corp — how do they compare? Honeywell International Inc trades at $207.1 (market cap $65.48B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Honeywell International Inc is far larger — about 5.8× BIO-TECHNE Corp's market cap, and Honeywell International Inc pays the higher dividend (1.36%). Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and BIO-TECHNE Corp for 63 Days on average.
| HON | TECH | |
|---|---|---|
Market Cap | $65.48B | $11.36B |
Volume | 2,047,782 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $248.79 | $72.61 |
52-Week Low | $188.14 | $43.31 |
Typical Hold Time | 90 Days | 63 Days |
Enterprise Value | $90.27B | $11.39B |
Dividend Yield | 1.36% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal despite strong fundamentals including a P/E of 8 and robust profitability margins. The company has beaten earnings estimates for three consecutive quarters and maintains a 66.7% analyst buy rating with a $259.25 consensus price target. Recent corporate developments include a $300 million refinery project win and quarterly dividend payments of $0.70 per share.
The outlook remains positive given HON's earnings momentum and strategic focus on automation post-spinoff, though technical weakness and rising debt-to-asset ratios pose near-term risks. Wall Street optimism is supported by strong profitability metrics and recent contract wins, while investors should monitor execution of the company's transformation strategy and macroeconomic pressures on industrial demand.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
